Literature DB >> 2129023

The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

J E Testa1, J P Quigley.   

Abstract

The correlation between urokinase-type plasminogen activator (uPA) expression and tumor cell invasion and metastasis has been well documented. Urokinase converts the zymogen plasminogen to plasmin, a trypsin-like enzyme with broad substrate specificities. Net uPA activity is determined not only by the amount of the enzyme itself, but also by its state of activation and the amount of specific plasminogen activator inhibitors (PAIs) present. Both uPA and its substrate, plasminogen, can bind to cells via specific membrane-associated receptors. Expression of uPA, uPA receptor (uPAR), and PAIs is regulated by growth factors, oncogenes, and other effector molecules. In the present review we discuss the interactions of uPA with its receptor, inhibitors, and substrate and how these interactions influence malignant behavior. We also review recent reports in which investigators have used anti-catalytic antibodies and/or gene transfection to demonstrate that uPA is directly involved in tumor cell invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129023     DOI: 10.1007/bf00049524

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  101 in total

1.  Binding of protease nexin-1 to the fibroblast surface alters its target proteinase specificity.

Authors:  S L Wagner; A L Lau; D D Cunningham
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

Review 2.  Growth factors in the regulation of pericellular proteolysis: a review.

Authors:  M Laiho; J Keski-Oja
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

3.  Lack of correlation between fibrinolysis and the transformed state of cultured mammalian cells.

Authors:  D M Mott; P H Fabisch; B P Sani; S Sorof
Journal:  Biochem Biophys Res Commun       Date:  1974-11-27       Impact factor: 3.575

Review 4.  Plasminogen activator inhibitors--a review.

Authors:  E K Kruithof
Journal:  Enzyme       Date:  1988

5.  Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis.

Authors:  R Flaumenhaft; D Moscatelli; O Saksela; D B Rifkin
Journal:  J Cell Physiol       Date:  1989-07       Impact factor: 6.384

6.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

7.  Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells.

Authors:  J E Testa; R L Medcalf; J F Cajot; W D Schleuning; B Sordat
Journal:  Int J Cancer       Date:  1989-05-15       Impact factor: 7.396

8.  Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

Authors:  P J Declerck; M De Mol; M C Alessi; S Baudner; E P Pâques; K T Preissner; G Müller-Berghaus; D Collen
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

9.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

10.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.

Authors:  R W Stephens; J Pöllänen; H Tapiovaara; K C Leung; P S Sim; E M Salonen; E Rønne; N Behrendt; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

View more
  37 in total

1.  Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Authors:  D Albo; D H Berger; J Vogel; G P Tuszynski
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

2.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits.

Authors:  A M Tester; N Ruangpanit; R L Anderson; E W Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.

Authors:  Young C Shin; William R Folk
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 4.  The role of cellular proteases and their inhibitors in invasion and metastasis. Introductionary overview.

Authors:  L Liotta
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

5.  Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3.

Authors:  Xian Wu Cheng; Masafumi Kuzuya; Kae Nakamura; Qun Di; Zexuan Liu; Takeshi Sasaki; Shigeru Kanda; Hai Jin; Guo-Ping Shi; Toyoaki Murohara; Mitsuhiro Yokota; Akihisa Iguchi
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 6.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

Review 7.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

8.  Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.

Authors:  S Sato; T Higashi; S Ouguchi; N Hino; T Tsuji
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

9.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

10.  Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.

Authors:  D Samid; S Shack; C E Myers
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.